BioLife Solutions, Inc. (FRA:BJX1)
Germany flag Germany · Delayed Price · Currency is EUR
21.60
0.00 (0.00%)
At close: Dec 4, 2025

BioLife Solutions Company Description

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals.

It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

BioLife Solutions, Inc.
Country United States
Founded 1987
Industry Biological Products, Except Diagnostic Substances
Employees 159
CEO Roderick de Greef

Contact Details

Address:
3303 Monte Villa Parkway
Bothell, Delaware 98021
United States
Phone 425 402 1400
Website biolifesolutions.com

Stock Details

Ticker Symbol BJX1
Exchange Frankfurt Stock Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
Roderick de Greef Chief Executive Officer
Troy Wichterman Chief Financial Officer
Karen Foster Chief Operating Officer